Trial NCT01125293

View at ClinicalTrials.gov 
Org. Study IDs: 09-280
Secondary IDs: R01FD003743 R01FD003743; X05310

Last trial update was posted on 2021-04-23

MeSH Interventions

Bortezomib Everolimus Rituximab

MeSH Conditions

Waldenstrom Macroglobulinemia

Other Conditions

Waldenstrom's Macroglobulinemia

Stopping Reasons

Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants observe a Very Good Partial Response or Better in the first 23 participants enrolled to Phase II.

Limitations And Caveats

N/A

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID